[1] UEBELHART D, MALAISE M, MARCOLONGO R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: A one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage, 2004,12(4):269-276.[2] CLEGG D O, REDA D J, HARRIS C L, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med, 2006,354(8):795-808.[3] MARTIN M S, VAN SELL S, DANTER J. Glucosamine and chondroitin: An appropriate adjunct treatment of symptomatic osteoarthritis of the knee. Orthop Nurs, 2012,31(3):160-166.[4] REGINSTER J Y. In people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo.Evid Based Med, 2012,17(5):152-153.[5] DOMAGALA F, MARTIN G, BOGDANOWICZ P, et al. Inhibition of interleukin-1β-induced activation of MEK/ERK pathway and DNA binding of NF-κB and AP-1: Potential mechanism for Diacerein effects in osteoarthritis. Biorheology, 2006,43(3):577-587.[6] DU SOUICH P, GARCIA A G, VERGES J, et al. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med, 2009,13(8):1451-1463.[7] HE Z X, JIN Y, ZHANG T M. Structure of chondroitin sulfate and its application in osteoarthritis therapy .Chin Pharm J(中国药学杂志),2012,47(5): 387-391.[8] MCALINDON T E, LAVALLEY M P, GULIN J P, et al. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA, 2000,283(11): 1469-1475.[9] GABAY C, MEDINGER-SADOWSKI C, GASCON D, et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: A randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum, 2011,63(11):3383-3391. RUBIO-TERRES C. An economic evaluation of chondroitin sulfate and non-steroidal anti-inflammatory drugs for the treatment of osteoarthritis. Data from the VECTRA study. Reumatol Clin, 2010,6(4):187-195. IAVAZZO C, ATHANASIOU S, PITSOUNI E, et al. Hyaluronic acid: An effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis. Eur Urol, 2007,51(6):1534-1540. DAMIANO R, CICIONE A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol, 2011, 3(5):223-232. CERVIGNI M, NATALE F, NASTA L, et al. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct, 2008,19(7):943-947. CERVIGNI M, NATALE F, NASTA L, et al. Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: Long-term treatment results.Int Urogynecol J, 2012,23(9):1187-1192. DAMIANO R, QUARTO G, BAVA I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: A placebo-controlled randomisedtrial. Eur Urol, 2011, 59(4):645-651. ZHANG G R, ZHANG C H, LIU A J, et al. Influence of cartilage polysaccharide on humoral immunity function of tumor-bearing mice.Mod Food Sci Tech(现代食品科技), 2009, 25(5):466-468. SAKAI S, AKIYAMA H, SATO Y, et al. Chondroitin sulfate intake inhibits the IgE-mediated allergic response by down-regulating Th2 responses in mice. J Biol Chem, 2006,281(29): 19872-19880. AKIYAMA H, SAKAI S, LINHARDT R J, et al. Chondroitin sulphate structure affects its immunological activities on murine splenocytes sensitized with ovalbumin.Biochem J, 2004,382(Pt 1):269-278. MOLLER I, PEREZ M, MONFORT J, et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: A randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage, 2010, 18 (1):32-40. VERGS J, MONTELL E, HERRERO M, et al. Clinical and histopathological improvement of psoriasis in patients with osteoarthritis treated with chondroitin sulfate: Report of 3 cases. Medicinaclínica, 2004,123(19):739-742. VERGES J, MONTELL E, HERRERO M, et al. Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: A serendipitous finding.Dermatol Online J, 2005,11(1):31. MAKSIMENKO A V, GOLUBYKH V L, TISCHENKO E G. Catalase and chondroitin sulfate derivatives against thrombotic effect induced by reactive oxygen species in a rat artery. Metab Eng, 2003,5(3):177-182. MOURAO P A, BOISSON-VIDAL C, TAPON-BRETAUDIERE J, et al. Inactivation of thrombin by a fucosylated chondroitin sulfate from echinoderm. Thromb Res, 2001,102(2):167-176. FONSECA R J, MOURAO P A. Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Thromb Haemost, 2006,96(6):822-929. KAPLAN M, AVIRAM M. Macrophage plasma membrane chondroitin sulfate proteoglycan binds oxidized low-density lipoprotein. Atherosclerosis, 2000, 149(1):5-17. YAO X Y. Study on lipid-decreasing effect of chondroitin sulfate polysaccharides from monopterusalbus bone.China Med Rep(中国医药导报), 2011,8(30):31-33. HAN L K, SUMIYOSHI M, TAKEDA T, et al. Inhibitory effects of chondroitin sulfate prepared from salmon nasal cartilage on fat storage in mice fed a high-fat diet. Int J Obes Relat Metab Disord, 2000,24(9):1131-1138. KURITA H. ber den einfluss des chon-droitin sulfates auf die experimentelle ath-erosklerose in kaninchen. Med J Shinshu Univ, 1955,1:23-27. GUTIERREZ S H, KURI M R, DEL CASTILLO E R. Cardiac role of the transcription factor NF-kappaB. Cardiovasc Hematol Disord Drug Targets, 2008,8(2):153-160. TAT S K, PELLETIER J P, VERGS J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: A basic science study. Arthritis Research and Therapy, 2007,9(6):117. OLSSON U, OSTERGREN-LUNDEN G, MOSES J. Glycosaminoglycan-lipoprotein interaction. Glycoconj J, 2001,18(10):789-797. JOMPHE C, GABRIAC M, HALE T M, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol, 2008, 102(1):59-65. HERRERO-BEAUMONT G, MARCOS M E, SANCHEZ-PERNAUTE O, et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol, 2008,154(4):843-851. SUGAHARA K, MIKAMI T. Chondroitin/dermatan sulfate in the central nervous system. Curr Opin Struct Biol, 2007,17(5):536-545. RHODES K E, FAWCETT J W. Chondroitin sulphate proteoglycans: Preventing plasticity or protecting the CNS?. J Anat, 2004,204(1):33-48. ROLLS A, SHECHTER R, LONDON A, et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: A role in microglia/macrophage activation. PLoS Med, 2008,5(8):171. ROLLS A, AVIDAN H, CAHALON L, et al. A disaccharide derived from chondroitin sulphate proteoglycan promotes central nervous system repair in rats and mice. Eur J Neurosci, 2004,20(8):1973-1983. ROLLS A, CAHALON L, BAKALASH S, et al. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. FASEB J, 2006,20(3):547-549. CANAS N, VALERO T, VILLARROYA M, et al. Chondroitin sulfate protects SH-SY5Y cells from oxidative stress by inducing heme oxygenase-1 via phosphatidylinositol 3-kinase/Akt. J Pharmacol Exp Ther, 2007,323(3):946-953. EGEA J, GARCIA A G, VERGES J, et al. Antioxidant, antiinflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans. Osteoarthritis Cartilage, 2010,18(1):24-27. MULLER A J, LETELIER M E, GALLEGUILLOS M A, et al. Comparison of the antioxidant effects of synovial fluid from equine metacarpophalangeal joints with those of hyaluronic acid and chondroitin sulfate. Am J Vet Res, 2010,71(4):399-404. LEE J Y, LEE S H, KIM H J, et al. The preventive inhibition of chondroitin sulfate against the CCl4-induced oxidative stress of subcellular level. Arch Pharm Res, 2004,27(3):340-345. CAMPO G M, AVENOSO A, CAMPO S, et al. Chondroitin-4-sulphate reduced oxidative injury in caerulein-induced pancreatitis in mice: The involvement of NF-kappaB translocation and apoptosis activation. Exp Biol Med (Maywood), 2008,233(6):741-752. CAMPO G M, AVENOSO A, CAMPO S, et al. The antioxidant activity of chondroitin-4-sulphate, in carbon tetrachloride-induced acute hepatitis in mice, involves NF-kappaB and caspaseactivation. Br J Pharmacol, 2008,155(6):945-956. ASIMAKOPOULOU A P, THEOCHARIS A D, TZANAKAKIS G N, et al. The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. In Vivo, 2008,22(3): 385-389. MONFORT J, NACHER M, MONTELL E, et al. Chondroitin sulfate and hyaluronic acid (500-730 kda) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Drugs Under Exp Clin Res, 2005,31(2):71-76. PUMPHREY C Y, THEUS A M, LI S, et al. Neoglycans, carbodiimide-modified glycosaminoglycans: A new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res, 2002,62(13):3722-3728. LIN H. Study on the Anti-Inflammatory and Anti-Tumor Effects of Shark Chondroitin Sulfate and Its Supersulfated Derivatives. Jinan:Shandong University, 2006. LIU K W, CHI Y,LV J. Therapeutic efficacy of shark chondroitin combined with chemotherapy in treatment of advanced non-small cell lung cancer.Chin J Clin Oncol Rehabil(中国肿瘤临床与康复), 2009,16(2):167-169. BEESON J G, ANDREWS K T, BOYLE M, et al. Structural basis for binding of plasmodium falciparum erythrocyte membrane protein 1 to chondroitin sulfate and placental tissue and the influence of protein polymorphisms on binding specificity. J Biol Chem, 2007,282(31): 22426-224236. BERGEFALL K, TRYBALA E, JOHANSSON M, et al. Chondroitin sulfate characterized by the E-disaccharide unit is a potent inhibitor of herpes simplex virus infectivity and provides the virus binding sites on gro2C cells. J Biol Chem, 2005,280(37):32193-32199. LAI J Y, LI Y T, CHO C H, et al. Nanoscale modification of porous gelatin scaffolds with chondroitin sulfate for corneal stromal tissue engineering.Int J Nanomedicine, 2012,7:1101-1114. FAN W X, MA X H, GE D, et al. Cryoprotectants for the vitrification of corneal endothelial cells. Cryobiology, 2009,58(1):28-36. KOBAYASHI F, YAMADA S, TAGUWA S, et al. Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus. Glycoconj J, 2012,29(4):211-220.